Bristol Myers Squibb's Alzheimer's Drug, BMS-986446, Granted FDA Fast Track Status

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 5 years. On October 2, Bristol Myers Squibb announced a development in its Alzheimer’s program: its experimental drug, BMS-986446, received Fast Track designation from the US FDA.

The designation expedites the review process for the drug, which is currently in Phase 2 testing for patients in the early stages of Alzheimer’s disease. In preclinical studies, the drug demonstrated a sharp reduction in tau uptake and spread, and protected against behavioral decline. The Fast Track status gives Bristol Myers Squibb an advantage in the competitive field of Alzheimer’s treatments.

The therapy targets the tau protein, which spreads in the brains of Alzheimer’s patients. By neutralizing this spread and promoting the clearance of pathological tau, BMS-986446 modifies the underlying course of the disease with the goal of slowing or delaying disease progression.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.